Novartis Ag (NVS) Accumulated Depreciation & Amortization (2016 - 2024)
Novartis Ag recorded quarterly Accumulated Depreciation & Amortization of -$9.4 billion in Q4 2024, up 0.61% quarter-over-quarter from -$9.5 billion in Q4 2023, and up 0.61% year-over-year from -$9.4 billion in Q1 2024.
Novartis Ag's Accumulated Depreciation & Amortization history runs 7 years deep, the most recent figure standing at -$9.4 billion for Q4 2024.
- In Q4 2024, Accumulated Depreciation & Amortization rose 0.61% year-over-year to -$9.4 billion; the TTM figure through Dec 2024 stood at -$9.4 billion (up 0.61% YoY), while the FY2024 annual figure was -$9.4 billion, up 0.61% from the prior year.
- Accumulated Depreciation & Amortization came in at -$9.4 billion for Q4 2024 at Novartis Ag, up from -$9.5 billion in the prior quarter.
- In the past five years, Accumulated Depreciation & Amortization ranged from a high of -$9.4 billion in Q4 2024 to a low of -$12.2 billion in Q4 2020.
- A 3-year average of -$10.4 billion and a median of -$9.5 billion in 2023 frame the typical range for Accumulated Depreciation & Amortization.
- Across the five-year window, Accumulated Depreciation & Amortization slumped 5443.67% in 2020 and advanced 0.61% in 2024, its largest moves.
- Novartis Ag's Accumulated Depreciation & Amortization stood at -$12.2 billion in 2020, then gained by 22.4% to -$9.5 billion in 2023, then grew by 0.61% to -$9.4 billion in 2024.
- According to Business Quant data, Accumulated Depreciation & Amortization over the past three periods registered -$9.4 billion, -$9.5 billion, and -$12.2 billion for Q4 2024, Q4 2023, and Q4 2020 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -9.44 Bn |
| Dec 31, 2024 | -9.44 Bn |
| Dec 31, 2023 | -9.50 Bn |
| Dec 31, 2023 | -9.50 Bn |
| Dec 31, 2020 | -12.24 Bn |
| Dec 31, 2020 | -12.24 Bn |
| Dec 31, 2019 | 229.00 Mn |
| Dec 31, 2019 | 229.00 Mn |
| Dec 31, 2018 | 22.02 Bn |
| Dec 31, 2018 | 22.02 Bn |
| Dec 31, 2017 | 16.50 Bn |
| Dec 31, 2017 | 16.50 Bn |
| Dec 31, 2016 | 21.08 Bn |
| Dec 31, 2016 | 21.08 Bn |